Mirum Pharma's Liver Treatment Hits Phase 2B Endpoint, Shares Soar to All-Time High
Summary
Mirum Pharmaceuticals announced highly positive Phase 2b results for volixibat, its oral treatment for primary sclerosing cholangitis (PSC), meeting the primary endpoint with statistically significant improvements in pruritus. This significant clinical milestone for a rare and progressive liver disease is a major de-risking event for the company's pipeline, validating its therapeutic approach and driving shares to an all-time high. The company has scheduled a pre-New Drug Application (NDA) meeting with the FDA for this summer and plans to submit the NDA in the second half of the year. This positive development follows other recent clinical progress, including positive Phase 2b results for brelovitug, further strengthening Mirum's product portfolio.
At the time of this announcement, MIRM was trading at $109.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $40.00 to $110.49. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.